Brain Atrophy in Multiple Sclerosis: Mechanisms, Clinical Relevance and Treatment Options

Autoimmunity Highlights - Italy
doi 10.1186/s13317-019-0117-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Association of Retinal and Macular Damage With Brain Atrophy in Multiple Sclerosis

PLoS ONE
Multidisciplinary
2011English

Establishing Pathological Cut-Offs of Brain Atrophy Rates in Multiple Sclerosis

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2015English

Epigenetic Mechanisms in Multiple Sclerosis: Implications for Pathogenesis and Treatment

The Lancet Neurology
Neurology
2013English

Thalamic Atrophy Without Whole Brain Atrophy Is Associated With Absence of 2-Year NEDA in Multiple Sclerosis

Frontiers in Neurology
Neurology
2019English

Sample Sizes for Brain Atrophy Outcomes in Trials for Secondary Progressive Multiple Sclerosis

Neurology
Neurology
2008English

The Clinical Relevance of Force Platform Measures in Multiple Sclerosis: A Review

Multiple Sclerosis International
Neurology
2013English

Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method

PLoS ONE
Multidisciplinary
2016English

Current Treatment Options for Postmenopausal Vaginal Atrophy

International Journal of Women's Health
GynecologyOncologyMidwiferyMaternityObstetrics
2018English

Patterns of Blood-Brain Barrier Impairment and Clinical Features in Multiple Sclerosis.

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
1993English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy